BR100 Increased By (0.77%)
BR30 Increased By (0.52%)
KSE100 Increased By (0.66%)
KSE30 Increased By (0.68%)
AGHA 7.78 Increased By ▲ 0.03 (0.39%)
BECO 5.20 Increased By ▲ 0.01 (0.19%)
BML 57.59 Decreased By ▼ -1.07 (-1.82%)
BOP 34.22 Increased By ▲ 0.53 (1.57%)
CNERGY 10.77 Increased By ▲ 0.16 (1.51%)
CSIL 5.43 Increased By ▲ 0.13 (2.45%)
FCCL 54.90 Increased By ▲ 1.16 (2.16%)
FFL 16.72 Increased By ▲ 0.26 (1.58%)
FNEL 1.25 Increased By ▲ 0.03 (2.46%)
KEL 7.44 Increased By ▲ 0.16 (2.2%)
KOSM 5.85 Increased By ▲ 0.21 (3.72%)
LOTCHEM 29.74 Increased By ▲ 0.09 (0.3%)
MLCF 95.60 Decreased By ▼ -0.76 (-0.79%)
NBP 203.70 Increased By ▲ 0.17 (0.08%)
NCPL 58.00 Increased By ▲ 1.15 (2.02%)
NPL 69.30 Increased By ▲ 1.99 (2.96%)
OGDC 318.20 Decreased By ▼ -0.02 (-0.01%)
PACE 10.75 Increased By ▲ 0.12 (1.13%)
PAEL 42.90 Increased By ▲ 1.13 (2.71%)
PIBTL 16.80 Decreased By ▼ -0.01 (-0.06%)
PPL 221.23 Increased By ▲ 1.06 (0.48%)
PRL 51.51 Increased By ▲ 2.46 (5.02%)
PTC 70.80 Increased By ▲ 0.79 (1.13%)
SSGC 28.68 Decreased By ▼ -0.46 (-1.58%)
TBL 9.90 Increased By ▲ 0.13 (1.33%)
TELE 8.90 Increased By ▲ 0.08 (0.91%)
TPL 18.25 Increased By ▲ 1.08 (6.29%)
TPLP 12.96 Increased By ▲ 0.45 (3.6%)
TREET 22.70 Increased By ▲ 0.11 (0.49%)
TRG 59.92 Decreased By ▼ -0.30 (-0.5%)
By

NEW YORK: A Hawaii court ordered Bristol-Myers Squibb and Sanofi to pay the state $834 million over marketing claims for blood thinner, Plavix, according to news reports.

The two pharmaceutical giants said they intend to appeal the decision, which concluded that the companies engaged in unfair and deceptive business practices.

The state of Hawaii alleged the companies misled consumers about the benefit of using the drug, particularly for people of East Asian ancestry.

The drug makers “intend to appeal the trial court’s decision and we are confident in our success on appeal,” the companies said.

The state pointed to results showing the treatment did not work well for some patients of Asian or Pacific-island descent who could not properly metabolize the drug, according to the reports.

But the two companies disagreed, saying, “Leading cardiologists have examined the scientific evidence and continue to recommend Plavix as the standard of care for all its indications regardless of race or ethnicity.

Comments

Comments are closed for this article.